Evaxion out-licenses vaccine candidate EVX-B3 to MSD
Provided By GlobeNewswire
Last update: Sep 25, 2025
COPENHAGEN, Denmark, September 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has out-licensed its vaccine candidate EVX-B3 to MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) as per the option and license agreement entered between the two companies in September 2024.
Read more at globenewswire.com
